Muath Sheet Mohammed Ameen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muath Sheet Mohammed Ameen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Mohammed Mahmood Ahmed
College of Medicine, University of Halabja, Halabja 46018, Iraq
2 shared publications - Morteza Abazari
Experimental and Applied Pharmaceutical Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran
2 shared publications - Safa Momeni Badeleh
Department of Food and Drug Control, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publications - Afeefa Noor
Department of Pharmacy, Lloyd Institute of Management and Technology, Plot No.11, Knowledge Park-II, Greater Noida 201306, Uttar Pradesh, India
1 shared publication Alaa Abdul Rasool
Department of Pharmaceutics, College of Pharmacy, Baghdad University, Baghdad, Iraq
1 shared publication- Firas Aziz Rahi
Al-Mansour University College
1 shared publication
Latest Publications
- Open Access
- 30 June 2023
- Published by Knowledge University in Pharmacy and Applied Health Sciences
- Vol. 2 (1) , 46-66
Studying the Release Profile of 5-Fluorouracil Prepared By Controlled Porosity Osmotic System As A Colon Targeting
In this study, different formulas (F1-F7) containing 4 mg of 5-fluorouracil (5-FU) were prepared as a tablet in form of CPOP-CT. The core of these formulas contained citric acid, sodium chloride, LMCh, MMCh, ProSolv SMCC®90 and magnesium stearate mixed with 5-FU. The formulas were double coated by an inner layer containing chitosan and PEG-400 and outer layer as an enteric coating containing Eudragit®L100-55, triethyl citrate and talc. The solubility of 5-FU in different dissolution media (pH 5, pH 7) was studied. The results indicated increase of LMCh and decrease of citric acid lead to slow the release of 5-FU for F1, F2, F3, F4, F5, F6 and F7 in simulated colonic fluid with 61%, 29%, 32%, 43%, 52%, 39% and 68%, respectively within 21 h. In addition, the release rate of 5-FU was affected by changing the weight gain percentages of semipermeable CAM. 6% and 10% weight gains of F3 released 5-FU completely within times (t100% ) of 46 h and 65 h, respectively which are acceptable with colonic transit time (78 h) compared with 14% weight gain (t100% = 135 h). In SCF, the enzymatic effect on the release of 5-FU within 21 h for F6 was studied which synthetic almond emulsin β-glucosidase and human fecal enzyme increased release of 5-FU with 26% and 39%, respectively compared to 18% release with no enzyme. Degradation effect of these enzymes made pores in semipermeable to release drugs and then modulate the drug kinetic from zero order into first order.
- 30 June 2023
- Published by Knowledge University in Pharmacy and Applied Health Sciences
- Vol. 2 (1) , 46-66
Open AccessStudying the Release Profile of 5-Fluorouracil Prepared By Controlled Porosity Osmotic System As A Colon Targeting
In this study, different formulas (F1-F7) containing 4 mg of 5-fluorouracil (5-FU) were prepared as a tablet in form of CPOP-CT. The core of these formulas contained citric acid, sodium chloride, LMCh, MMCh, ProSolv SMCC®90 and magnesium stearate mixed with 5-FU. The formulas were double coated by an inner layer containing chitosan and PEG-400 and outer layer as an enteric coating containing Eudragit®L100-55, triethyl citrate and talc. The solubility of 5-FU in different dissolution media (pH 5, pH 7) was studied. The results indicated increase of LMCh and decrease of citric acid lead to slow the release of 5-FU for F1, F2, F3, F4, F5, F6 and F7 in simulated colonic fluid with 61%, 29%, 32%, 43%, 52%, 39% and 68%, respectively within 21 h. In addition, the release rate of 5-FU was affected by changing the weight gain percentages of semipermeable CAM. 6% and 10% weight gains of F3 released 5-FU completely within times (t100% ) of 46 h and 65 h, respectively which are acceptable with colonic transit time (78 h) compared with 14% weight gain (t100% = 135 h). In SCF, the enzymatic effect on the release of 5-FU within 21 h for F6 was studied which synthetic almond emulsin β-glucosidase and human fecal enzyme increased release of 5-FU with 26% and 39%, respectively compared to 18% release with no enzyme. Degradation effect of these enzymes made pores in semipermeable to release drugs and then modulate the drug kinetic from zero order into first order.
- Open Access
Development and Evaluation of Nanoformulations Containing Timur Oil and Rosemary Oil for Treatment of Topical Fungal Infections
The pervasiveness of fungal infections is an issue for skin health globally, and there are a reported 40 million cases in developed and developing countries. Novel drug delivery systems provide better therapeutic efficacy over conventional drug therapy due to their lower side effects and toxicity. Furthermore, combinations of essential oils can represent alternative therapies for fungal infections that are resistant to synthetic drugs. This study is aimed at developing Timur oil into a nanoemulgel and evaluating its antifungal effects. The development of the formulation involved the preparation of a nanoemulsion by the titration method, followed by its evaluation for various physicochemical properties. The antifungal activity of the nanoemulgel against Candida albicans was evaluated. The zone of inhibition was determined using the disk diffusion method. The results show that the developed nanoemulgel has a particle size of 139 ± 6.11 nm, a PDI of 0.309, and a zeta potential of −19.12 ± 2.73 mV. An in vitro drug release study showed a sustained release of 70 ± 0.289% of the drug over a period of 24 h. The % drug permeation across the skin was found to be 79.11 ± 0.319% over 24 h. However, the amount of drug retained in the skin was 56.45 µg/g. The flux for the nanoemulgel was found to be 94.947 µg/cm2/h, indicating a better permeability profile. The nanoemulgel formulation showed a zone of inhibition of 15 ± 2.45 mm, whereas the 1% ketoconazole cream (marketed preparation) exhibited a zone of inhibition of 13 ± 2.13 mm. The results of this study suggest that developed nanoemulgel containing Timur oil and rosemary oil has the potential to be used for treating topical fungal infections caused by Candida albicans.
Open AccessDevelopment and Evaluation of Nanoformulations Containing Timur Oil and Rosemary Oil for Treatment of Topical Fungal Infections
The pervasiveness of fungal infections is an issue for skin health globally, and there are a reported 40 million cases in developed and developing countries. Novel drug delivery systems provide better therapeutic efficacy over conventional drug therapy due to their lower side effects and toxicity. Furthermore, combinations of essential oils can represent alternative therapies for fungal infections that are resistant to synthetic drugs. This study is aimed at developing Timur oil into a nanoemulgel and evaluating its antifungal effects. The development of the formulation involved the preparation of a nanoemulsion by the titration method, followed by its evaluation for various physicochemical properties. The antifungal activity of the nanoemulgel against Candida albicans was evaluated. The zone of inhibition was determined using the disk diffusion method. The results show that the developed nanoemulgel has a particle size of 139 ± 6.11 nm, a PDI of 0.309, and a zeta potential of −19.12 ± 2.73 mV. An in vitro drug release study showed a sustained release of 70 ± 0.289% of the drug over a period of 24 h. The % drug permeation across the skin was found to be 79.11 ± 0.319% over 24 h. However, the amount of drug retained in the skin was 56.45 µg/g. The flux for the nanoemulgel was found to be 94.947 µg/cm2/h, indicating a better permeability profile. The nanoemulgel formulation showed a zone of inhibition of 15 ± 2.45 mm, whereas the 1% ketoconazole cream (marketed preparation) exhibited a zone of inhibition of 13 ± 2.13 mm. The results of this study suggest that developed nanoemulgel containing Timur oil and rosemary oil has the potential to be used for treating topical fungal infections caused by Candida albicans.
- RetractedOpen Access
- 31 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114943
RETRACTED: Chitosan-decorated and tripolyphosphate-crosslinked pH-sensitive niosomal nanogels for Controlled release of fluoropyrimidine 5-fluorouracil
- 31 May 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 114943
RetractedOpen AccessRETRACTED: Chitosan-decorated and tripolyphosphate-crosslinked pH-sensitive niosomal nanogels for Controlled release of fluoropyrimidine 5-fluorouracil
- 20 February 2023
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 18 (3) , 1213-1228
Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine
- 20 February 2023
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 18 (3) , 1213-1228
Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine
- Open Access
- 30 December 2022
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 6(40),p. 21-28
Preparation and evaluation of lipid matrix microencapsulation for drug delivery of azilsartan kamedoxomil
The aim of the work is to consolidate azilsartan-kamedoxomil (AZM) into lipid matrix controlled-release microparticles to enhance its permeability because AZM belongs to Biopharmaceutical classification (BCS) IV which characterized by poor permeability and to protect AZM from light and humidity and execute a prolonged release profile. Materials and methods. A reversed-phase HPLC method was created and validated to estimate the drug. AZM microparticles formulations were invented using melt dispersion technique and waxy materials such as carnuba wax, beeswax, stearic acid in the ratio of waxy-substance: drug ranging from 0.25: 1 to 1:1 and stabilizer namely; tween 80 and Poloxamer 407 in ratio of stabilizer: drug ranging from 0.5:1 to 1:1. Azilsartan formulations were assessed for azilsartan-medoxomil content, loading, entrapment efficiency, the zeta potential,the particle size, the morphology by scanning electronic microscopy (SEM), and in-vitro release profile. Results. Zeta potential results for microparticle formulations using beeswax and carnuba range from -21.1 mV to -26.6 mV and -20.6 mV to -26.7 mV, respectively. This difference indicates that the azilsartan microparticles containing stearic acid are better stabilized with zeta potential of 25.3 - 29.7 mV. Furthermore, the release from azilsartan microparticle formulations containing stearic acid exceeded 80 % after 8 h and remained for 24 h while release from beeswax did not exceed 65 % after the same period and less than 60 % in case of carnuba formulations Conclusions. The formulation (AZSP4) exhibited the highest zeta potential and released exceeding 80 % of AZM over the course of 8 hours and remained over a day. AZSP4 microparticles formulation containing, poloxamer 407, in a 0.8:0.8:1 drug: stearic acid: poloxamer ratio proved the ability of stearic acid microencapsulation employing poloxamer as stabilizer in a certain ratio can prolong the release of AZM
- 30 December 2022
- Published by Private Company Technology Center in ScienceRise: Pharmaceutical Science
- No. 6(40),p. 21-28
Open AccessPreparation and evaluation of lipid matrix microencapsulation for drug delivery of azilsartan kamedoxomil
The aim of the work is to consolidate azilsartan-kamedoxomil (AZM) into lipid matrix controlled-release microparticles to enhance its permeability because AZM belongs to Biopharmaceutical classification (BCS) IV which characterized by poor permeability and to protect AZM from light and humidity and execute a prolonged release profile. Materials and methods. A reversed-phase HPLC method was created and validated to estimate the drug. AZM microparticles formulations were invented using melt dispersion technique and waxy materials such as carnuba wax, beeswax, stearic acid in the ratio of waxy-substance: drug ranging from 0.25: 1 to 1:1 and stabilizer namely; tween 80 and Poloxamer 407 in ratio of stabilizer: drug ranging from 0.5:1 to 1:1. Azilsartan formulations were assessed for azilsartan-medoxomil content, loading, entrapment efficiency, the zeta potential,the particle size, the morphology by scanning electronic microscopy (SEM), and in-vitro release profile. Results. Zeta potential results for microparticle formulations using beeswax and carnuba range from -21.1 mV to -26.6 mV and -20.6 mV to -26.7 mV, respectively. This difference indicates that the azilsartan microparticles containing stearic acid are better stabilized with zeta potential of 25.3 - 29.7 mV. Furthermore, the release from azilsartan microparticle formulations containing stearic acid exceeded 80 % after 8 h and remained for 24 h while release from beeswax did not exceed 65 % after the same period and less than 60 % in case of carnuba formulations Conclusions. The formulation (AZSP4) exhibited the highest zeta potential and released exceeding 80 % of AZM over the course of 8 hours and remained over a day. AZSP4 microparticles formulation containing, poloxamer 407, in a 0.8:0.8:1 drug: stearic acid: poloxamer ratio proved the ability of stearic acid microencapsulation employing poloxamer as stabilizer in a certain ratio can prolong the release of AZM